PL3700902T3 - Inhibitory trpc6 - Google Patents

Inhibitory trpc6

Info

Publication number
PL3700902T3
PL3700902T3 PL18800513.6T PL18800513T PL3700902T3 PL 3700902 T3 PL3700902 T3 PL 3700902T3 PL 18800513 T PL18800513 T PL 18800513T PL 3700902 T3 PL3700902 T3 PL 3700902T3
Authority
PL
Poland
Prior art keywords
trpc6
inhibitors
Prior art date
Application number
PL18800513.6T
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Lana Louise Smith Keenan
Michael D. Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Boehringer Ingelheim International Gmbh
Hydra Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Hydra Biosciences, Llc filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3700902T3 publication Critical patent/PL3700902T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18800513.6T 2017-10-27 2018-10-25 Inhibitory trpc6 PL3700902T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09
PCT/EP2018/079276 WO2019081637A1 (en) 2017-10-27 2018-10-25 CARBONYL PYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS

Publications (1)

Publication Number Publication Date
PL3700902T3 true PL3700902T3 (pl) 2023-09-04

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18800513.6T PL3700902T3 (pl) 2017-10-27 2018-10-25 Inhibitory trpc6
PL20197194.2T PL3786160T3 (pl) 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20197194.2T PL3786160T3 (pl) 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6

Country Status (28)

Country Link
US (4) US10889568B2 (pl)
EP (2) EP3786160B1 (pl)
JP (2) JP7217273B6 (pl)
KR (2) KR20200125758A (pl)
CN (1) CN111527078B (pl)
AU (2) AU2018355743B2 (pl)
BR (1) BR112020007818A2 (pl)
CA (1) CA3078769A1 (pl)
CL (2) CL2020001097A1 (pl)
CY (1) CY1126109T1 (pl)
DK (2) DK3700902T3 (pl)
ES (2) ES2946274T3 (pl)
FI (1) FI3700902T3 (pl)
HR (2) HRP20220991T1 (pl)
HU (2) HUE059450T2 (pl)
IL (2) IL274039B (pl)
LT (2) LT3700902T (pl)
MX (1) MX2020004283A (pl)
PE (1) PE20210154A1 (pl)
PH (1) PH12020550503A1 (pl)
PL (2) PL3700902T3 (pl)
PT (2) PT3700902T (pl)
RS (2) RS63535B1 (pl)
SG (2) SG11202003367TA (pl)
SI (2) SI3786160T1 (pl)
TW (2) TWI780511B (pl)
WO (1) WO2019081637A1 (pl)
ZA (1) ZA202002372B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202003367TA (en) * 2017-10-27 2020-05-28 Boehringer Ingelheim Int Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
JP7291711B2 (ja) * 2018-02-15 2023-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６阻害剤
US11370771B2 (en) * 2018-02-16 2022-06-28 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
US20220152023A1 (en) * 2019-04-12 2022-05-19 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
WO2021160625A1 (en) 2020-02-11 2021-08-19 Klinikum Rechts Der Isar Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
WO2021209510A1 (en) 2020-04-16 2021-10-21 Boehringer Ingelheim International Gmbh Inhibitors of trpc6 for treating respiratory conditions
AR121846A1 (es) * 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
CA3229735A1 (en) 2021-10-15 2023-04-20 Boehringer Ingelheim International Gmbh Trpc6 inhibitory compounds for treating sepsis
WO2023106421A1 (ja) * 2021-12-06 2023-06-15 国立大学法人熊本大学 Trpc6の発現を抑制する方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
ES2192192T3 (es) 1992-12-02 2003-10-01 Pfizer Dieteres de catecol como inhibidores selectivos de pde iv.
EP1122242B1 (en) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
NZ523526A (en) 2000-07-20 2004-10-29 Neurogen Corp Diaryl piperazines as capsaicin receptor ligands
MXPA03011629A (es) 2001-06-15 2004-07-01 Yamanouchi Pharmaceuticals Co Derivado de fenilpiridincarbonilpiperazina.
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
JP2008515972A (ja) 2004-10-13 2008-05-15 ニューロジェン・コーポレーション メラニン濃縮ホルモン受容体のリガンドとしてのアリール置換８−アザビシクロ［３．２．１］オクタン化合物
DE102005044814A1 (de) 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
TWI325423B (en) 2005-10-28 2010-06-01 Lilly Co Eli Kinase inhibitors
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
MX2009009873A (es) 2007-03-15 2009-09-24 Novartis Ag Compuestos organicos y sus usos.
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
JP2012512877A (ja) 2008-12-18 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セロトニン５−ｈｔ２ｂ受容体阻害剤
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
EP2486033A1 (en) 2009-10-09 2012-08-15 Irm Llc Compounds and compositions as modulators of gpr119 activity
BR112012011823A2 (pt) 2009-11-18 2019-09-24 Novartis Ag métodos e composições para tratar tumores sólidos e outras malignidades
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
HUE037850T2 (hu) 2010-04-27 2018-09-28 Mitsubishi Tanabe Pharma Corp Új amidszármazék és alkalmazása gyógyszerként
EP2569300A1 (en) 2010-05-13 2013-03-20 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
MX338707B (es) 2010-07-29 2016-04-28 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP6581970B2 (ja) * 2013-05-27 2019-09-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US9783533B2 (en) 2014-01-06 2017-10-10 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
HUE061989T2 (hu) 2016-03-16 2023-09-28 Kura Oncology Inc Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások
CA3028815A1 (en) 2016-06-20 2017-12-28 Rutgers, The State University Of New Jersey Therapeutic compounds
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
WO2018159827A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
TW201902875A (zh) 2017-03-15 2019-01-16 美商亞瑟尼克斯公司 聯芳基哌啶醯胺化合物及其使用方法
SG11202003367TA (en) 2017-10-27 2020-05-28 Boehringer Ingelheim Int Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
JP7291711B2 (ja) 2018-02-15 2023-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐｃ６阻害剤
US11370771B2 (en) 2018-02-16 2022-06-28 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6

Also Published As

Publication number Publication date
US10800757B2 (en) 2020-10-13
AU2018355743A1 (en) 2020-05-14
JP7217273B2 (ja) 2023-02-02
EP3700902B1 (en) 2023-03-08
AU2018355743B2 (en) 2022-04-14
CY1126109T1 (el) 2023-11-15
US20190169168A1 (en) 2019-06-06
LT3786160T (lt) 2022-09-26
IL277493B (en) 2022-02-01
RS64271B1 (sr) 2023-07-31
LT3700902T (lt) 2023-06-26
PT3786160T (pt) 2022-08-19
IL274039A (en) 2020-06-30
JP2021008503A (ja) 2021-01-28
ZA202002372B (en) 2023-10-25
CA3078769A1 (en) 2019-05-02
ES2924933T3 (es) 2022-10-11
CN111527078A (zh) 2020-08-11
FI3700902T3 (fi) 2023-05-25
CN111527078B (zh) 2023-06-02
SI3786160T1 (sl) 2022-11-30
SI3700902T1 (sl) 2023-10-30
US10889568B2 (en) 2021-01-12
KR20200095467A (ko) 2020-08-10
HRP20230502T1 (hr) 2023-09-15
AU2020250185B2 (en) 2022-04-14
CL2020001097A1 (es) 2020-08-28
MX2020004283A (es) 2021-10-21
EP3786160B1 (en) 2022-07-13
US20210163449A1 (en) 2021-06-03
JP2021500390A (ja) 2021-01-07
DK3700902T3 (en) 2023-05-22
DK3786160T3 (da) 2022-08-22
TWI780511B (zh) 2022-10-11
PT3700902T (pt) 2023-05-30
ES2946274T3 (es) 2023-07-14
PL3786160T3 (pl) 2022-10-24
CL2020002562A1 (es) 2021-01-15
SG10202011632RA (en) 2021-01-28
IL274039B (en) 2021-08-31
JP6979502B2 (ja) 2021-12-15
HRP20220991T1 (hr) 2022-11-11
KR20200125758A (ko) 2020-11-04
EP3700902B8 (en) 2023-08-02
USRE49699E1 (en) 2023-10-17
AU2020250185A1 (en) 2020-11-12
EP3700902A1 (en) 2020-09-02
TW202120494A (zh) 2021-06-01
WO2019081637A1 (en) 2019-05-02
HUE062460T2 (hu) 2023-11-28
TW201930294A (zh) 2019-08-01
HUE059450T2 (hu) 2022-11-28
US20190169167A1 (en) 2019-06-06
SG11202003367TA (en) 2020-05-28
JP7217273B6 (ja) 2024-02-08
PH12020550503A1 (en) 2021-03-22
IL277493A (en) 2020-11-30
BR112020007818A2 (pt) 2020-10-20
PE20210154A1 (es) 2021-01-26
EP3786160A1 (en) 2021-03-03
RS63535B1 (sr) 2022-09-30
TWI780246B (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
HK1259232A1 (zh) Menin-mll的取代抑制劑及其使用方法
EP3541932A4 (en) CRISPR-CAS9 INHIBITORS
PL3700902T3 (pl) Inhibitory trpc6
ME03759B (me) Inhibitori bromodomena
IL267291B (en) Actonucleotidase inhibitors and methods of using them
GB201705263D0 (en) Novel inhibitors
IL259796A (en) Aza-benzimidazole inhibitors of pad4
IL257061A (en) Inhibitors of ezh2
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
LT3621694T (lt) Lrrc33 inhibitoriai ir jų panaudojimas
IL274504A (en) 2ACSS inhibitors and methods of their use
ZA201907136B (en) Ip6k inhibitors
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
SG11202000621VA (en) Inhibitors of ror?
EP3370763A4 (en) CD200 INHIBITORS AND METHODS OF USE
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
ZA201807614B (en) Bromodomain inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
AU2017904351A0 (en) Inhibitors of necroptosis
AU2015903172A0 (en) Inhibitors of necroptosis
AU2015900416A0 (en) Inhibitors of necroptosis